List/Grid

Sol-Gel Technologies Announces Participation in Upcoming Investor Conference

NESS ZIONA, Israel, April 18, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol–Gel” or the “Company”), a clinical–stage ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top–line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE ...
© 2019 Market Portal Egypt. All rights reserved.